FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149803495> ?p ?o ?g. }

• W2149803495 endingPage "1128" @default.
• W2149803495 startingPage "1122" @default.
• W2149803495 abstract "Current guidelines do not yet provide any recommendations for adjuvant chemotherapy in patients with upper tract urothelial carcinoma managed with radical nephroureterectomy. We evaluated whether an adjuvant chemotherapeutic regimen would affect the clinical outcome in patients with high risk upper tract urothelial carcinoma.We identified 873 patients who had undergone radical nephrouretectomy for localized upper tract urothelial carcinoma at 14 Japanese institutions between 1993 and 2011. We assessed whether the type of regimen, such as methotrexate, vinblastine, doxorubicin and cisplatin, and gemcitabine and cisplatin, in an adjuvant setting, could affect the subsequent clinical outcome of patients with upper tract urothelial carcinoma.On multivariate analysis pathological T stage, tumor grade, lymphovascular invasion and lymph node involvement were prognostic factors for recurrence-free survival and cancer specific survival. We defined 229 patients with 3 or more of these factors as the high risk group. In an analysis according to adjuvant regimen, Kaplan-Meier curves showed that the 1 and 2-year recurrence-free survival rates in the methotrexate, vinblastine, doxorubicin and cisplatin treated group were 71.4% and 47.9%, which were significantly higher than in the gemcitabine and cisplatin treated group (48.2% and not reached, p=0.022) or those not treated with adjuvant chemotherapy (53.4% and 39.6%, p=0.039). Similar results were observed in terms of cancer specific survival.Our study showed that pT3-4, tumor grade 3, positive lymphovascular invasion and lymph node involvement were independent risk factors for disease mortality in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. In the high risk group methotrexate, vinblastine, doxorubicin and cisplatin adjuvant chemotherapy contributed to improve subsequent mortality compared to gemcitabine and cisplatin or no adjuvant chemotherapy." @default.
• W2149803495 created "2016-06-24" @default.
• W2149803495 creator A5000242187 @default.
• W2149803495 creator A5000552159 @default.
• W2149803495 creator A5004000376 @default.
• W2149803495 creator A5010396290 @default.
• W2149803495 creator A5011820683 @default.
• W2149803495 creator A5016346897 @default.
• W2149803495 creator A5017328054 @default.
• W2149803495 creator A5022746763 @default.
• W2149803495 creator A5028006869 @default.
• W2149803495 creator A5029144059 @default.
• W2149803495 creator A5029310212 @default.
• W2149803495 creator A5032752800 @default.
• W2149803495 creator A5033437812 @default.
• W2149803495 creator A5037191523 @default.
• W2149803495 creator A5047759311 @default.
• W2149803495 creator A5049786841 @default.
• W2149803495 creator A5053961273 @default.
• W2149803495 creator A5072727806 @default.
• W2149803495 creator A5079063344 @default.
• W2149803495 creator A5082251044 @default.
• W2149803495 creator A5086644568 @default.
• W2149803495 creator A5086644570 @default.
• W2149803495 date "2015-04-01" @default.
• W2149803495 modified "2023-09-25" @default.
• W2149803495 title "Impact of an Adjuvant Chemotherapeutic Regimen on the Clinical Outcome in High Risk Patients with Upper Tract Urothelial Carcinoma: A Japanese Multi-Institution Experience" @default.
• W2149803495 cites W1509139787 @default.
• W2149803495 cites W1527366898 @default.
• W2149803495 cites W1545795076 @default.
• W2149803495 cites W1590018990 @default.
• W2149803495 cites W1593348050 @default.
• W2149803495 cites W1710217806 @default.
• W2149803495 cites W1721273399 @default.
• W2149803495 cites W1970462534 @default.
• W2149803495 cites W1975918912 @default.
• W2149803495 cites W1980525903 @default.
• W2149803495 cites W1987639526 @default.
• W2149803495 cites W2003123210 @default.
• W2149803495 cites W2028949946 @default.
• W2149803495 cites W2038111129 @default.
• W2149803495 cites W2046308359 @default.
• W2149803495 cites W2072065123 @default.
• W2149803495 cites W2085833972 @default.
• W2149803495 cites W2087061074 @default.
• W2149803495 cites W2089328416 @default.
• W2149803495 cites W2091949712 @default.
• W2149803495 cites W2097304520 @default.
• W2149803495 cites W2105398102 @default.
• W2149803495 cites W2134526917 @default.
• W2149803495 cites W2159142738 @default.
• W2149803495 cites W2171141475 @default.
• W2149803495 cites W2171883057 @default.
• W2149803495 cites W4252621956 @default.
• W2149803495 doi "https://doi.org/10.1016/j.juro.2014.10.022" @default.
• W2149803495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25444957" @default.
• W2149803495 hasPublicationYear "2015" @default.
• W2149803495 type Work @default.
• W2149803495 sameAs 2149803495 @default.
• W2149803495 citedByCount "25" @default.
• W2149803495 countsByYear W21498034952015 @default.
• W2149803495 countsByYear W21498034952016 @default.
• W2149803495 countsByYear W21498034952017 @default.
• W2149803495 countsByYear W21498034952018 @default.
• W2149803495 countsByYear W21498034952019 @default.
• W2149803495 countsByYear W21498034952020 @default.
• W2149803495 countsByYear W21498034952021 @default.
• W2149803495 countsByYear W21498034952022 @default.
• W2149803495 countsByYear W21498034952023 @default.
• W2149803495 crossrefType "journal-article" @default.
• W2149803495 hasAuthorship W2149803495A5000242187 @default.
• W2149803495 hasAuthorship W2149803495A5000552159 @default.
• W2149803495 hasAuthorship W2149803495A5004000376 @default.
• W2149803495 hasAuthorship W2149803495A5010396290 @default.
• W2149803495 hasAuthorship W2149803495A5011820683 @default.
• W2149803495 hasAuthorship W2149803495A5016346897 @default.
• W2149803495 hasAuthorship W2149803495A5017328054 @default.
• W2149803495 hasAuthorship W2149803495A5022746763 @default.
• W2149803495 hasAuthorship W2149803495A5028006869 @default.
• W2149803495 hasAuthorship W2149803495A5029144059 @default.
• W2149803495 hasAuthorship W2149803495A5029310212 @default.
• W2149803495 hasAuthorship W2149803495A5032752800 @default.
• W2149803495 hasAuthorship W2149803495A5033437812 @default.
• W2149803495 hasAuthorship W2149803495A5037191523 @default.
• W2149803495 hasAuthorship W2149803495A5047759311 @default.
• W2149803495 hasAuthorship W2149803495A5049786841 @default.
• W2149803495 hasAuthorship W2149803495A5053961273 @default.
• W2149803495 hasAuthorship W2149803495A5072727806 @default.
• W2149803495 hasAuthorship W2149803495A5079063344 @default.
• W2149803495 hasAuthorship W2149803495A5082251044 @default.
• W2149803495 hasAuthorship W2149803495A5086644568 @default.
• W2149803495 hasAuthorship W2149803495A5086644570 @default.
• W2149803495 hasConcept C121608353 @default.
• W2149803495 hasConcept C126322002 @default.
• W2149803495 hasConcept C126894567 @default.
• W2149803495 hasConcept C143998085 @default.
• W2149803495 hasConcept C2776694085 @default.
• W2149803495 hasConcept C2777132456 @default.

• next